Although SST5-selective SRLs can inhibit PRL release in human prolactinomas, the in vitro studies conducted to date show that they have a weaker effect on PRL inhibition than do DAs [8, 9]. Here, PRL is linked to prolactin-producing pituitary gland adenoma.